iCAD (ICAD) - Long-Term Debt to Capital

Brandmark of iCAD Inc. (ICAD)

The historical price action of iCAD, Inc. (ICAD) demonstrates the impact of the transition to cloud subscriptions, which increases ARR and constitutes 0.00. The business relies on high-margin licensing of AI algorithms for mammogram analysis without production costs. Furthermore, the implementation of software in MRI centers creates long-term technical customer lock-in, ensuring regular payments for system updates for the developer.

icadmed.com (ICAD): Long-Term Debt to Capital from 07/04/2022 to 08/02/2025
Brand item of iCAD, Inc.

Assessing the debt load is critical for understanding the issuer's financial stability. This indicator measures the proportion of long-term borrowings relative to equity, determining the business's degree of dependence on external financing. By analyzing the ratio of liabilities exceeding one year to equity, an investor can track leverage dynamics. For iCAD, Inc. (ICAD), its high-margin SaaS model means a low debt level confirms the efficiency of free cash flow generation, which minimizes default risks while scaling AI solutions.

Competing companies

Long-Term Debt to Equity Ratio BeiGene Ltd.|Long-Term Debt to Capital HALO|Long-Term Debt to Capital RVMD (Revolution Medicines Corp)|AAPG - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio cgoncology.com CGON|URGN: Long-Term Debt to Capital|BCAX - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital PSNL|ERAS (Erasca Oncology) - Long-Term Liabilities to Capital|DCTH - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient ymabs.com (YMAB)|Aura Biosciences (AURA) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient candeltx.com (CADL)|Accuray Inc. - Long-Term Debt to Capital|SLS - Long-Term Debt to Equity Ratio|Actuate Therapeutics, Inc. - Long-Term Debt to Equity Ratio|CTOR: Long-Term Debt to Capital|Long-Term Debt to Equity tuhurabio.com HURA|Protara Therapeutics Inc (TARA) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital FATE (Fate Therapeutics Corp)|Long-Term Liabilities to Capital Aadi Bio|TCRX (TScan Therapeutics) - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital championsoncology.com (CSBR)|XBiotech - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio CEL-SCI Corp. CVM|OS Therapies Inc - Long-Term Debt to Capital|RADX - Long-Term Debt to Capital|Long-Term Debt to Capital artivabio.com|Long-Term Debt to Capital Ratio Adlai Nortye|VERU - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient Tempest Therapeutics Inc|XLO (Xilio Therapeutics, Inc.) - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital RENB (renovarobio.com)|MURA - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio Kairos Pharma Limited KAPA|OKUR: Long-Term Debt to Capital|CytoMed Therapeutics (GDTC) - Long-Term Debt to Equity Ratio|curis.com - Long-Term Debt to Equity Ratio|Apollomics (APLM) - Ratio of Long-Term Indebtedness to Capital|THAR: Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Advanced Biomed Corp|Long-Term Debt to Capital GNPX (Genprex)|Long-Term Debt to Equity Ratio calidibio.com (CLDI)|Long-Term Debt to Capital SBFM (Sunshine Biopharma)|Long-Term Debt to Capital Xenetic Biosciences Inc. XBIO|Salarius Pharmaceuticals (SLRX) - Long-Term Debt to Capital|PPBT - Long-Term Debt to Capital Ratio|AONC (aoncology.com) - Long-Term Debt to Capital|BeiGene Ltd. (BGNE) - Long-Term Debt to Equity Ratio|CKPT (Checkpoint Therapeutics, Inc) - Long-Term Debt to Capital|Long-Term Debt to Capital ELEV|Long-Term Debt to Equity Ikena Oncology, Inc. IKNA|Long-Term Debt to Capital Ratio notablelabs.com (NTBL)|Viracta Therapeutics, Inc. - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio MorphoSys Inc MOR|NAYA (NAYA Bio) - Long-Term Debt to Capital|AAPGV: Long-Term Liabilities to Capital